Curaleaf supports NHS trial on CBD for Parkinson's symptoms

We’re proud to announce a new partnership between Curaleaf Laboratories and The Medical Cannabis Clinicians Society - a collaboration designed to close the education gap that continues to hold back patient access in the UK. While the UK is now the second largest medical cannabis market in Europe, fewer than 10% of the patients who could benefit are currently receiving treatment. One of the biggest barriers? A lack of education for clinicians. Education has always been central to Curaleaf’s strategy, and this partnership builds on that foundation, creating a stronger platform to empower prescribers and ultimately improve patient care. As Professor Michael Barnes Chair of MCCS, said: “The Society is very grateful to have the support of Curaleaf Laboratories… with the ultimate goal of enabling more patients to benefit from these therapies.” We’re excited to be taking this step forward — because with the right knowledge and support, we believe the UK medical cannabis journey is only just beginning. Read more about our partnership via Business of Cannabis here: https://brnw.ch/21wVVbm

Strengthening clinician education is essential if the UK is to realise the full potential of its medical cannabis framework. As Jonathan Hodgson, UK MD at Curaleaf International, explained: "We’ve helped patients and clinicians alike address unmet clinical needs through unlicensed medicines for a long time. While the adoption of medical cannabis is only in its infancy, we want to help widen access to this option." This partnership between Curaleaf Laboratories and The Medical Cannabis Clinicians Society reflects a long-term commitment to advancing standards, building confidence across the healthcare community, and ensuring the sector can grow responsibly. Read more via Business of Cannabis | Europe: https://lnkd.in/e_UT4M49

From Farm to Bedside: Medical Cannabis and its Potential in Global Health 🌱 There are many public health challenges across the world, including chronic pain conditions and healthcare inequalities. A review published in Complementary Therapies in Medicine offers a strategic perspective on medical cannabis and the journey from cultivation to clinical use. The review proposes a new approach, based on the CORE framework (Care, Outreach, Research, Education), which has been curated to guide responsible development and delivery of medical cannabis from “farm to bedside.” At Curaleaf International, we believe collaboration, research, and education are key to unlocking medical cannabis’ potential while ensuring safe, evidence-based patient access. Read the full article here: https://lnkd.in/ekQ7wh4X #MedicalCannabisResearch #CuraleafInternational #CannabisResearch

Could medical cannabis unlock a £13.3 billion boost for the UK economy? That’s the question at the heart of our latest campaign with Curaleaf Clinic. The research, developed with Cebr, reveals how medical cannabis could help thousands of people with long-term health conditions get back to work, restoring independence for individuals and injecting billions into the economy The challenge is huge: - 2.8 million people in the UK are currently locked out of employment by long-term illness - 62% say they’ve run out of traditional treatment options. The report calls for clearer NHS pathways, wider access, and government-funded research to give patients real choice and the chance to rebuild their lives At the centre of the campaign are powerful patient voices - like Fatma, who told us: “Not being able to get out of bed and go to work made me feel as if my identity was being stripped away. I now have the ability to work, lead a team, and regain my independence.” The story has already made headlines across the Mirror, Express, Daily Star and Metro. Read the full report linked in the comments A huge thank you to Curaleaf Clinic, Cebr and the patients who openly shared their experiences

The team at Ethos Cannabis believes medical cannabis care should be rooted in science, not guesswork. In her latest op-ed, Brooke Worster, MD, FACP, Chief Medical Consultant at Ethos Cannabis & Enterprise Director of Supportive Oncology at Jefferson Health, shares how Ethos’ partnership with Thomas Jefferson University is generating real-world data to better understand how patients use cannabis—and translating those insights into education, product development, and improved patient care. By aligning healthcare providers, dispensary staff, and researchers, we’re working to bridge the gap between research and real-world use, ensuring patients receive informed, compassionate guidance. 📖 Read Dr. Worster’s full piece to see how Pennsylvania’s program can set a national example for cannabis research and care: https://lnkd.in/gvwcSnqU

The UK’s medical cannabis market is growing fast, but patient access still lags behind other European countries. Curaleaf Laboratories and the Medical Cannabis Clinicians Society are partnering to provide CPD-accredited training that equips clinicians to prescribe safely and confidently. 🔗 https://lnkd.in/e_UT4M49 How can education unlock the full potential of medical cannabis in the UK? Mentions: Jonathan Hodgson, Professor Michael Barnes, Curaleaf Laboratories, Curaleaf International, The Medical Cannabis Clinicians Society (MCCS), Prohibition Partners, Dalgety, The British Pain Society

In this observational study of patients with chronic pain using opioids, medical cannabis authorization was not associated with a statistically significant decrease in opioid milligram equivalents (OME) over time. https://ow.ly/OtL650X0CoX

📢 Agenda Announcement: Building Prescriber Confidence Seven years after medical cannabis was legalised in the UK, prescribing remains concentrated in private clinics, with no mandated training requirements for clinicians. To support safe and confident prescribing, Prof Mike Barnes, Chair of the The Medical Cannabis Clinicians Society (MCCS), will lead a session on Best Practice, Training, and Governance. Session highlights: ∘ Latest Good Practice Guidelines for CBPM prescribing ∘ Strategies to ensure safe, effective, and compliant patient care ∘ Training and governance approaches to build prescriber confidence ∘ Reducing variation in clinical practice to improve patient access 📅 Date: 25th November 2025 🎟️ https://lnkd.in/g4NQDJF7 Join healthcare professionals and industry leaders at the Cannabis Health Symposium to learn how to confidently navigate the evolving medical cannabis landscape.

Foley & Lardner LLP partner Kyle Faget authored the Clinical Leader article, “What The #FDA Says About Investigator Responsibilities in DCTs,” examining the U.S. Food and Drug Administration’s September 2024 guidance on conducting decentralized clinical trials (#DCTs) for drugs, biological products, and medical devices. #clinicaltrials

Fresh insights from the INTEGRA-D™ clinical trial: Achieving 100% success rate in defibrillation efficacy tests during the implant procedure for the first 100 patients! Learn more here: https://lnkd.in/gS3dJvvt CAUTION-CCM-D is an investigational medical device. It is not approved by the U.S. Food and Drug Administration (FDA) for commercial distribution.